GlobeNewswire

Scipher Medicine and Grupo Amarey Announce First PrismRA® Patient Tests Completed in Colombia
05/11/2026
DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine, a leading precision medicine company, today announced that the first patient tests under its strategic partnership with Grupo Amarey have been [...]
GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
05/11/2026
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward [...]
GENFIT : Information financière du troisième trimestre 2026 et point sur les activités de la Société
05/11/2026
La trésorerie et les équivalents de trésorerie s’élèvent à 95,6 millions d’euros au 30 septembre 2026 et permettent un financement des activités au-delà de fin 2028. La croissance attendue des revenus futurs, combinée [...]
Significant growth in both revenue and earnings
05/11/2026
ANNOUNCEMENT NR. 325 5 November 2026 Trading statement for Q1 2026/27 (1 July – 30 September 2026) Significant growth in both revenue and earnings Revenue was up by 28% in Q1 2026/27 to DKK 160.0 million from DKK 124.6 [...]
RAMSAY SANTE : Unaudited interim results at the end of September 2026
05/11/2026
PRESS RELEASE Paris, 5 th November 2026 Unaudited interim results at the end of September 2026 Ramsay Santé delivers solid first-quarter performance, with continued revenue growth and improved operational performance [...]
RAMSAY SANTE : résultats intermédiaires au 30 septembre 2026
05/11/2026
COMMUNIQUÉ DE PRESSE Paris, 5 novembre 2026 Résultats trimestriels non audités à fin septembre 2026 Ramsay Santé affiche une solide performance au premier trimestre, avec une croissance continue de son chiffre d’ [...]
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
05/11/2026
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting ® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO ® [...]
Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL
05/11/2026
Les résultats de l’étude ELSPIRE seront présentés en «late-breaking» lors de The Liver Meeting ® 2026 et publiés simultanément dans la revue phare de l’AASLD, HEPATOLOGY À la semaine 52, 85,3 % des patients recevant [...]
Elevar Therapeutics Announces FDA PDUFA Date for Resubmitted New Drug Application for Rivoceranib in Combination With Camrelizumab for Use as a First-line Systemic Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
05/11/2026
FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months FORT LEE [...]
KFSH Riyadh Earns Davos Healthcare’s Global Elite Five-Star Medallion, Ranking Among Top 5% of Evaluated Hospitals
05/11/2026
RIYADH, Saudi Arabia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) in Riyadh has received Davos Healthcare’s Global Elite Five-Star Medallion, the highest distinction in [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
05/11/2026
Bagsværd, Denmark. 5 November 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Resolution Therapeutics Announces Positive Interim Phase I/II EMERALD Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease
05/11/2026
Six-month interim data showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation versus an external control RTX001 was well tolerated with no infusion-related serious adverse reactions; [...]
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
05/11/2026
First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD) Presentation to take place on Monday, [...]
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
05/11/2026
In real-world studies, up to 93% of patients experienced improvement or stabilization in liver stiffness with ultrasound elastography, with many patients moving into lower liver stiffness categories one year after [...]
Rectify Pharmaceuticals Presents Translational Data on RTY-406 at AASLD 2026 Liver Meeting
05/11/2026
Presentation highlights preclinical characterization of RTY-406, an oral, once-daily investigational therapy targeting underlying drivers of hepatobiliary diseases BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rectify [...]
GenomOncology Integrates ARUP Laboratories’ Jalapheno Phenotype-Matching Tool Into GO Pathology Workbench Under Multiyear Exclusive Agreement
05/11/2026
Gene-level phenotype-matching scores from patient Human Phenotype Ontology (HPO) terms now feed directly into variant prioritization for rare disease exome, genome, and large-panel germline testing, alongside new [...]
Regen BioPharma, Inc. Provides Shareholder Update on Company’s Activities and Direction
05/11/2026
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) Update on Regen’s recent activities (i.e.: debt payoff, financing, potential joint ventures): The Company has recently paid off [...]
Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry
05/11/2026
The 6-month target lesion primary patency (TLPP) 1 and access circuit primary patency (ACPP) 2 for patients in the arteriovenous fistula (AVF) cohort were 92.7% and 76.7%, respectively The real-world patency results [...]
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
05/11/2026
New investor presentation outlines scientific rationale for combining Ampligen’s immune-stimulating activity with daraxonrasib’s targeted RAS inhibition to potentially prolong clinical benefit Previously reported [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum